GlassScriptPhysician profile
Lindsey A Young
NPI 1962571133
$1,719.13
in general payments reported to CMS, 2019-2025
14 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $207 · 2021: $205 · 2022: $249 · 2023: $192 · 2024: $408 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,025.19 | 2019-2025 | Total30, Precision7, Precision 1 |
| Ocular Therapeutix, INC. | $158.07 | 2024 | Dextenza |
| Glaukos Corporation | $144.41 | 2023 | Istent Inject Trabecular Micro-Bypass System, Istent Infinite Trabecular Micro-Bypass System Model Is3, Istent Trabecular Micro-Bypass Stent System |
| Johnson & Johnson Vision Care, INC. | $82.23 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $52.70 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.66 | 2019-2021 | |
| Optos, INC. | $40.00 | 2021 | |
| Harrow Eye, LLC | $37.85 | 2024-2025 | Vevye, Triesence |
| Abbvie INC. | $26.05 | 2022 | |
| Merck Sharp & Dohme LLC | $24.44 | 2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $23.42 | 2020 | |
| Bausch & Lomb Americas INC. | $20.44 | 2024 | Xiidra, Miebo |
| Shire North American Group INC | $16.53 | 2019 | |
| Dompe US, INC. | $15.14 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.